Jaguar health provides company updates and reports 2022 second quarter financials

Prescription product net revenue of $2.9 million in q2 2022 increased approximately 12.0% quarter over quarter, over q1 2022; and increased approximately 641% year over year, over mytesi® net revenue in q2 2021 core initiatives: ontarget phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) adding international sites, targeting completion of enrollment 1h 2023 expected presentation in december 2022 of results of a third-party, investigator-initiated proof-of-concept trial of crofelemer for short bowel syndrome (sbs), supporting the potential for expanded patient access through programs in europe in 2023 ongoing launch of canalevia®-ca1 for treatment of chemotherapy-induced diarrhea (cid) in dogs reminder: jaguar to host investor webcast monday, august 22nd at 8:30 a.m. eastern regarding second quarter 2022 financials and company updates; click here to register for webcast san francisco, ca / accesswire / august 22, 2022 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today provided company updates and reported consolidated second-quarter 2022 financial results.
JAGX Ratings Summary
JAGX Quant Ranking